GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma
This study uncovered that lenvatinib could be a potent ICD inducer, which could trigger ERS via increasing ROS levels in HCC cells, which present valuable insights into the mechanism of lenvatinib-induced ICD in HCC cells. Collectively, our findings highlight the significant therapeutic potential of the combination of targeting GPX2 and treatment with lenvatinib for HCC.
Authors
- Yingzheng Tan
- Caixi Tang (ORCID: https://orcid.org/0000-0003-4046-4451)
- Wenliang Tan (ORCID: https://orcid.org/0000-0003-2142-7030)
- Qingbin Wang (ORCID: https://orcid.org/0000-0003-3283-9989)
- Xun Chen (ORCID: https://orcid.org/0000-0002-4922-8116)
- Zhijian Zhao (ORCID: https://orcid.org/0000-0003-2069-6001)
- Meiyuan Huang
- Tao Xu (ORCID: https://orcid.org/0000-0001-9806-1335)
- Lei Yang (ORCID: https://orcid.org/0000-0002-3707-4877)
Institutions
- Central South University (CN)
- Sun Yat-sen University (CN)
- Anhui Medical University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Zhuzhou Central Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1186/s12967-025-06468-5
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Health Commission of Hunan Province
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province